dr. tripathy on impact of olaparib approval in brca-positive breast cancer
Published 6 years ago • 240 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
3:27
tripathy discusses a study of talazoparib in brca-mutated advanced breast cancer
-
2:46
dr. brufsky on the fda approval of olaparib in brca breast cancer
-
1:27
dr. litton on the impact of parp inhibitors in breast cancer
-
0:49
dr. tung discusses the role of olaparib in breast cancer
-
1:17
dr. traina on parp inhibition in brca-mutated breast cancer
-
5:43
using olaparib in gbrca1/2 breast cancer
-
1:15
dr. robson on the toxicity profile of olaparib in breast cancer
-
2:19
phase iii results of olaparib for brca breast cancer
-
5:49
perspectives on the olympia study of adjuvant olaparib in early breast cancer | nadine tung
-
6:18
value of olaparib in brca-mutated advanced ovarian cancer
-
2:12
dr. patel on an analysis of olaparib and cediranib for ovarian cancer
-
6:04
germline brca mutations in tnbc
-
6:03
olaparib maintenance for recurrent ovarian cancer
-
3:50
olaparib beneficial for brca-mutated her2-negative breast cancer
-
1:25
olaparib in ovarian cancer
-
5:00
olympia: adjuvant olaparib delays recurrence of brca-mutant breast cancer | judy garber
-
5:19
parp inhibitors for brca-associated tnbc
-
1:48
dr. penson on olaparib monotherapy vs chemo for ovarian cancer
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer